N/A N=53 Bone Level Tapered Multi-Center Study
Tooth Loss
Primary: Mean Crestal Bone Level Change — 0.5; 0.5 Change in Mean crestal bone levels (mm) — p=.950
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=58 Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)
Epilepsies, Partial
Primary: Treatment Failure — 11; 11 Participants
N/A N=40 Effect of VR on Pain and Patient Satisfaction in Adults Receiving GNRFA
Pain · Patient Satisfaction
Primary: Peak Pain Intensity During Genicular RFA Procedure — 75.8; 70.6 units on a scale
Phase 2 N=60 Vitamin D Supplementation in RNA-seq Profiles of Single-core Prostate Samples, Among Veterans
Prostate Cancer · Vitamin D Deficiency · Stress Reaction
Primary: Percentage of Participants With Change in Transcriptional Profiles After Vitamin D Supplementation. — 100 percentage of subjects
N/A N=42 Added Sugar Intake and Brain Structure and Function
Child Development
Primary: Added Sugars Intake Relationship to Brain Structure — 0.119; -0.231; 0.345; 0.384 Pearson correlation coefficient
N/A N=84 Plantar Heel Pain: Multisegment Foot Motion and Muscle Function, FFI Translation, and Evaluation of Treatments
Plantar Fasciitis
Primary: Worst Pain — 5.96; 5.74; 3.91; 4.08 score — p=0.660
Phase 3 N=400 Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Liposarcoma, Dedifferentiated
Primary: Progression-free Survival (PFS) — 8.18; 8.38; 7.16 Months — p=0.0956
N/A N=54 Food Intake Response to Short-Term Modifications of Metabolism in Humans
Healthy Volunteers
Primary: 24-hour Energy Expenditure (kcal) — 2256; 2166; 2563; 2487 kcal
Phase 2 N=20 Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid
Eyelid Sebaceous Gland Carcinoma
Primary: Sentinel Lymph Node Positivity — 2 Participants
Phase 4 N=74 The HOME Study (HPN With OMEGA-3)
Patients Requiring Home Parenteral Nutrition
Primary: Change of Liver Function Parameters From Baseline to Visit 2 — 0.0606; -0.0703 normalized sum- no unit — p=0.025
Phase 2 N=15 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Acute Leukemia · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia/Lymphoma
Primary: Probability of Acute Graft Versus Host Disease (GVHD) — 0; 30 Percent of participants
N/A N=489 Implementing and Sustaining a Sleep Treatment to Improve Community Mental Part 1: Implementation Health Outcomes
Sleep Disorder · Circadian Dysregulation
Primary: Patient-level Outcome: Patient-Reported Outcomes Measurement Information System - Sleep Disturbance — 63.86; 62.10; 62.81; 62.80 T-score — p=<0.001
Phase 1 N=20 A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV
HIV-1-infection
Primary: Number of Participants Reporting Local Solicited Adverse Events Signs and Symptoms: Pain and/or Tenderness — 4; 0; 6; 7 Participants
N/A N=1,390 Assessing Testing Strategies for Safe Return to K-12 Schools in an Underserved Population
Covid19
Primary: Overall Rate of All COVID-19 Cases in Schools. — 453; 297 Completed tests — p=0.25
N/A N=43 Mechanisms of Fall Resistance to Diverse Slipping Conditions
Slipping and Falls
Primary: Fall Rates - Slips on Turns — 0; 7.94; 1.59; 23.44 Percent of trials resulting in falls.